# Analysis of the Potential Savings of Rivaroxaban Events Versus Vitamin K Antagonists Events

> **NCT03462446** · — · COMPLETED · sponsor: **Bayer** · enrollment: 249 (actual)

## Conditions studied

- Atrial Fibrillation

## Interventions

- **DRUG:** Rivaroxaban (Xarelto, BAY59-7939)
- **DRUG:** Vitamin K antagonists (VKAs)

## Key facts

- **NCT ID:** NCT03462446
- **Lead sponsor:** Bayer
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2015-06-01
- **Primary completion:** 2016-05-01
- **Final completion:** 2016-05-01
- **Target enrollment:** 249 (ACTUAL)
- **Last updated:** 2018-03-12

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03462446

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03462446, "Analysis of the Potential Savings of Rivaroxaban Events Versus Vitamin K Antagonists Events". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT03462446. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*